Which has better valuation & earnings, CRMD or ALEC?

CorMedix has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 1.90 $163.05M $2.13 3.54 Alector $21.05M 7.96 -$142.93M -$1.19 N/A

Is CRMD or ALEC more profitable?

CorMedix has a net margin of 45.25% compared to Alector's net margin of -680.83%. CorMedix's return on equity of 45.57% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets CorMedix 45.25% 45.57% 24.76% Alector -680.83% -295.17% -40.95%

Does the media favor CRMD or ALEC?

In the previous week, CorMedix had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Alector. CorMedix's average media sentiment score of 0.00 equaled Alector'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALEC or ALLO?

In the previous week, Allogene Therapeutics had 4 more articles in the media than Alector. MarketBeat recorded 5 mentions for Allogene Therapeutics and 1 mentions for Alector. Allogene Therapeutics' average media sentiment score of 0.32 beat Alector's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TECX or ALEC?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for Alector. Tectonic Therapeutic's average media sentiment score of 0.83 beat Alector's score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALEC or SPRY?

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Alector. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 1 mentions for Alector. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Alector's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ALEC or AVTE?

Alector presently has a consensus price target of $3.63, indicating a potential upside of 140.07%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Alector (ALEC) Competitors

$1.51 0.00 (0.00%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$1.52 +0.00 (+0.33%)

As of 08/3/2026 07:34 PM Eastern

Compare

ALEC vs. CRMD, ALLO, TECX, SPRY, and AVTE

Should you buy Alector stock or one of its competitors? MarketBeat compares Alector with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alector include CorMedix (CRMD), Allogene Therapeutics (ALLO), Tectonic Therapeutic (TECX), ARS Pharmaceuticals (SPRY), and Aerovate Therapeutics (AVTE).

How does Alector compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

CorMedix has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.90	$163.05M	$2.13	3.54
Alector	$21.05M	7.96	-$142.93M	-$1.19	N/A

CorMedix has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Alector has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, CorMedix had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Alector. CorMedix's average media sentiment score of 0.00 equaled Alector'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix presently has a consensus target price of $14.86, indicating a potential upside of 96.78%. Alector has a consensus target price of $3.63, indicating a potential upside of 140.07%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CorMedix has a net margin of 45.25% compared to Alector's net margin of -680.83%. CorMedix's return on equity of 45.57% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Alector	-680.83%	-295.17%	-40.95%

Summary

CorMedix beats Alector on 11 of the 15 factors compared between the two stocks.

How does Alector compare to Allogene Therapeutics?

Alector (NASDAQ:ALEC) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Allogene Therapeutics had 4 more articles in the media than Alector. MarketBeat recorded 5 mentions for Allogene Therapeutics and 1 mentions for Alector. Allogene Therapeutics' average media sentiment score of 0.32 beat Alector's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alector presently has a consensus target price of $3.63, indicating a potential upside of 140.07%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 363.16%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Alector has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	7.96	-$142.93M	-$1.19	N/A
Allogene Therapeutics	$20K	31,753.80	-$190.89M	-$0.77	N/A

Allogene Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Allogene Therapeutics' return on equity of -56.45% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Alector has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

85.8% of Alector shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Allogene Therapeutics beats Alector on 12 of the 17 factors compared between the two stocks.

How does Alector compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Tectonic Therapeutic has higher earnings, but lower revenue than Alector. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Alector	$21.05M	7.96	-$142.93M	-$1.19	N/A

Tectonic Therapeutic has a net margin of 0.00% compared to Alector's net margin of -680.83%. Tectonic Therapeutic's return on equity of -32.33% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Alector	-680.83%	-295.17%	-40.95%

Tectonic Therapeutic has a beta of 3.28, suggesting that its stock price is 228% more volatile than the broader market. Comparatively, Alector has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Tectonic Therapeutic presently has a consensus price target of $79.40, suggesting a potential upside of 184.38%. Alector has a consensus price target of $3.63, suggesting a potential upside of 140.07%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, equities research analysts plainly believe Tectonic Therapeutic is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for Alector. Tectonic Therapeutic's average media sentiment score of 0.83 beat Alector's score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic beats Alector on 12 of the 16 factors compared between the two stocks.

How does Alector compare to ARS Pharmaceuticals?

Alector (NASDAQ:ALEC) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Alector. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 1 mentions for Alector. ARS Pharmaceuticals' average media sentiment score of 0.70 beat Alector's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Alector currently has a consensus target price of $3.63, indicating a potential upside of 140.07%. ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 416.48%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alector has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	7.96	-$142.93M	-$1.19	N/A
ARS Pharmaceuticals	$98.99M	5.48	-$171.30M	-$2.01	N/A

85.8% of Alector shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ARS Pharmaceuticals has a net margin of -200.00% compared to Alector's net margin of -680.83%. ARS Pharmaceuticals' return on equity of -153.61% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

ARS Pharmaceuticals beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Aerovate Therapeutics?

Alector (NASDAQ:ALEC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Alector has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Aerovate Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Aerovate Therapeutics' return on equity of -90.19% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Alector had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Alector and 0 mentions for Aerovate Therapeutics. Alector's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Alector	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics has lower revenue, but higher earnings than Alector. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	7.96	-$142.93M	-$1.19	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

85.8% of Alector shares are held by institutional investors. 8.3% of Alector shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alector presently has a consensus price target of $3.63, indicating a potential upside of 140.07%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Alector beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$167.65M	$3.55B	$6.86B	$12.44B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-1.27	7.29	280.72	24.99
Price / Sales	7.96	1,264.45	588.10	90.57
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	5.39	16.89	11.02	6.21
Net Income	-$142.93M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-0.66%	0.31%	0.80%	1.29%
1 Month Performance	-26.70%	-7.40%	-4.17%	-3.59%
1 Year Performance	-2.58%	47.13%	61.47%	18.38%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	1.4945 of 5 stars	$1.51 flat	$3.63 +140.1%	+4.1%	$167.65M	$21.05M	N/A	270	Upcoming Earnings Analyst Forecast
CRMD CorMedix	1.7245 of 5 stars	$7.87 -2.2%	$14.86 +88.8%	-35.1%	$631.54M	$311.71M	3.69	30
ALLO Allogene Therapeutics	2.5901 of 5 stars	$1.74 -4.4%	$8.52 +389.8%	+70.4%	$628.18M	N/A	N/A	310	Positive News
TECX Tectonic Therapeutic	3.3796 of 5 stars	$30.37 -3.9%	$79.40 +161.4%	+34.7%	$596.46M	N/A	N/A	120	Upcoming Earnings
SPRY ARS Pharmaceuticals	2.745 of 5 stars	$5.94 -1.0%	$28.20 +374.7%	-68.2%	$595.82M	$84.28M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. CRMD, ALLO, TECX, SPRY, and AVTE

How does Alector compare to CorMedix?

Summary

How does Alector compare to Allogene Therapeutics?

Summary

How does Alector compare to Tectonic Therapeutic?

Summary

How does Alector compare to ARS Pharmaceuticals?

Summary

How does Alector compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. CRMD, ALLO, TECX, SPRY, and AVTE

How does Alector compare to CorMedix?

Which has better valuation & earnings, CRMD or ALEC?

Which has more risk & volatility, CRMD or ALEC?

Does the media favor CRMD or ALEC?

Do analysts recommend CRMD or ALEC?

Do insiders and institutionals believe in CRMD or ALEC?

Is CRMD or ALEC more profitable?

Summary

How does Alector compare to Allogene Therapeutics?

Does the media prefer ALEC or ALLO?

Do analysts prefer ALEC or ALLO?

Which has better valuation & earnings, ALEC or ALLO?

Is ALEC or ALLO more profitable?

Which has more risk and volatility, ALEC or ALLO?

Do institutionals and insiders believe in ALEC or ALLO?

Summary

How does Alector compare to Tectonic Therapeutic?

Which has stronger earnings and valuation, TECX or ALEC?

Is TECX or ALEC more profitable?

Which has more volatility and risk, TECX or ALEC?

Do analysts recommend TECX or ALEC?

Does the media favor TECX or ALEC?

Do institutionals & insiders hold more shares of TECX or ALEC?

Summary

How does Alector compare to ARS Pharmaceuticals?

Does the media refer more to ALEC or SPRY?

Which has more volatility and risk, ALEC or SPRY?

Do analysts prefer ALEC or SPRY?

Which has preferable earnings & valuation, ALEC or SPRY?

Do institutionals and insiders have more ownership in ALEC or SPRY?

Is ALEC or SPRY more profitable?

Summary

How does Alector compare to Aerovate Therapeutics?

Which has more risk and volatility, ALEC or AVTE?

Is ALEC or AVTE more profitable?

Does the media refer more to ALEC or AVTE?

Which has preferable valuation and earnings, ALEC or AVTE?

Do institutionals & insiders believe in ALEC or AVTE?

Do analysts recommend ALEC or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools